T1	Participants 113 151	patients with metastatic breast cancer
T2	Participants 4 38	Eastern Cooperative Oncology Group
T3	Participants 162 391	162 women (90 premenopausal and 72 postmenopausal) with metastatic breast cancer randomized to receive cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF) on two Eastern Cooperative Oncology Group (ECOG) protocols
